The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Value Outlook For The Biosimilar Monoclonal Antibodies Market Through 2030?
The biosimilar monoclonal antibodies market has shown robust expansion in recent years. This market is expected to expand from $10.64 billion in 2025 to $11.29 billion in 2026, advancing at a compound annual growth rate (CAGR) of 6.2%. The significant growth observed historically can be linked to the expensive nature of originator biologics, an increasing incidence of chronic and autoimmune conditions, the expiry of patents for leading monoclonal antibodies, rising healthcare expenditure, and a gradual improvement in regulatory guidelines for biosimilars.
The biosimilar monoclonal antibodies market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $14.58 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this growth during the projected period include the broadening of biosimilar development pipelines, an escalating need for economical biologic therapies, a rise in approvals within developing markets, innovations in biopharmaceutical production, and favorable government initiatives for biosimilar integration. Key developments expected during the forecast timeframe encompass the increasing embrace of economical biosimilar monoclonal antibodies, expanded application of biosimilars in cancer and autoimmune conditions, enhanced acceptance of biosimilars by medical professionals and patients, broadened regulatory clearances across international markets, and a heightened emphasis on improving availability of biologic treatments.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp
Which Growth Factors Are Strengthening The Biosimilar Monoclonal Antibodies Market Landscape?
The increasing occurrence of autoimmune diseases is anticipated to boost the growth of the biosimilar monoclonal antibodies market in the future. Autoimmune conditions involve the immune system erroneously targeting and attacking the body’s own tissues and organs. This rise in autoimmune diseases is largely caused by a surge in environmental triggers, such as pollution and various chemicals, which can disturb immune system equilibrium and foster irregular immune responses. Biosimilar monoclonal antibodies are instrumental in tackling the growing prevalence of autoimmune diseases by offering affordable, effective, and widely available targeted treatments that manage overactive immune responses in affected individuals. For example, data from February 2024, sourced from Arthritis Australia, an Australia-based non-profit organization, projects that by 2025, an estimated 212,136 males and 362,137 females will be diagnosed with rheumatoid arthritis (RA). These figures are expected to increase by 2040 to approximately 280,040 males and 479,828 females. Thus, the escalating incidence of autoimmune diseases is a significant driver for the biosimilar monoclonal antibodies market expansion.
What Are The Core Segment Classifications In The Biosimilar Monoclonal Antibodies Market?
The biosimilar monoclonal antibodies market covered in this report is segmented –
1) By Type: Biopharmaceuticals, Other Types
2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab
3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications
Subsegments:
1) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals
2) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics
Which Trends Are Contributing To Changes In The Biosimilar Monoclonal Antibodies Market?
Leading companies in the biosimilar monoclonal antibody market are focused on developing biosimilar forms of monoclonal antibodies to present cost-effective alternatives to existing monoclonal antibody therapies, thereby enhancing accessibility and affordability within healthcare. An intravenous formulation denotes an antibody preparation designed for direct administration into the bloodstream through a vein, ensuring a rapid therapeutic impact. For instance, in May 2024, Bio-Thera Solutions, a China-based biopharmaceutical company, and Biogen Inc., a US-based biopharmaceutical company, introduced TOFIDENCE (tocilizumab-bavi) in an intravenous formulation in the United States. The U.S. Food and Drug Administration had granted approval for TOFIDENCE in September 2023 for addressing moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. Upon its launch, TOFIDENCE is supplied in three vial sizes for intravenous infusion: 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL, with subcutaneous formulations slated for later release.
Who Are The Businesses Driving Activity In The Biosimilar Monoclonal Antibodies Market?
Major companies operating in the biosimilar monoclonal antibodies market are Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy’s Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.
Access The Complete Biosimilar Monoclonal Antibodies Market Report:
Which Area Represents The Largest Portion Of The Biosimilar Monoclonal Antibodies Market?
North America was the largest region in the biosimilar monoclonal antibodies market in 2025. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Biosimilar Monoclonal Antibodies Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp
Browse Through More Reports Similar to the Global Biosimilar Monoclonal Antibodies Market 2026, By The Business Research Company
Biologics Market 2026
https://www.thebusinessresearchcompany.com/report/biologics-market
Pharmaceutical Drugs And Biologics Logistics Market 2026
Anti Asthmatics And Copd Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model